Ondine Announces Debt Financing

 
TIDMOBP 
 
Ondine Announces Debt Financing 
FOR:  ONDINE BIOMEDICAL INC. 
 
TSX, AIM SYMBOL:  OBP 
 
March 21, 2011 
 
Ondine Announces Debt Financing 
 
VANCOUVER, BRITISH COLUMBIA--(Marketwire - March 21, 2011) - Ondine Biomedical Inc. (TSX:OBP)(AIM:OBP) 
(the "Company" or "Ondine") a medical technology company developing photodisinfection based products, 
today announced that it has entered into a loan agreement with Carolyn Cross, Chairman, CEO and a 
shareholder of the Company, pursuant to which Ms. Cross advanced the Company C$500,000 (the "Loan"), 
demonstrating her continued support of the Company. 
 
The Loan is due on July 1, 2011 and is secured by a first charge on the proceeds of any future 
financing transaction. The Loan is interest free until the due date, but thereafter, the principal 
amount will accrue interest at a rate of 5% per annum payable monthly. The proceeds of the Loan will 
be used for the continued research and development of new products based on the Company's 
photodisinfection technology, including the Endowave(TM) product for the reduction of ventilator 
associated pneumonia (VAP) and the Company's MRSAid(TM) product for the decolonization of pathogenic 
bacteria, such as methicillin-resistant Staphylococcus aureus (MRSA), in the nose; for working 
capital; and for general corporate purposes. 
 
The loan agreement entered into by the Company and Ms. Cross constitutes a related party transaction 
for the purposes of the AIM Rules for Companies (the "Related Party Transaction"). Accordingly, the 
directors of the Company (excluding Ms. Cross), having consulted with its nominated adviser, consider 
the terms of the Related Party Transaction to be fair and reasonable insofar as the Company's 
shareholders are concerned. 
 
The material change report in respect of this transaction was not filed at least 21 days in advance of 
the closing of the Loan as the Company was in need of the funds. The Company considers the shortened 
timeframe to be reasonable under these circumstances. 
 
About Ondine Biomedical Inc. 
 
Ondine is developing non-antibiotic therapies for the treatment of a broad spectrum of bacterial, 
fungal and viral infections. The Company is focused on developing leading edge products utilizing its 
patented light-activated technology, primarily for the healthcare-associated infection (HAI) market. 
Photodisinfection provides broad-spectrum antimicrobial efficacy without encouraging the formation and 
spread of antibiotic resistance. The Company is based in Vancouver, British Columbia, Canada, with a 
research and development laboratory in Bothell, Washington, USA. For additional information, please 
visit the Company's website at: www.ondinebio.com. 
 
Forward-Looking Statements: 
 
Certain statements contained in this release containing words like "believe", "intend", "may", 
"expect" and other similar expressions, are forward-looking statements that involve a number of risks 
and uncertainties. Factors that could cause actual results to differ materially from those projected 
in the Company's forward-looking statements include the following: market acceptance of our 
technologies and products; our ability to obtain financing; our financial and technical resources 
relative to those of our competitors; our ability to keep up with rapid technological change; 
government regulation of our technologies; our ability to enforce our intellectual property rights and 
protect our proprietary technologies; the ability to obtain and develop partnership opportunities; the 
timing of commercial product launches; the ability to achieve key technical milestones in key products 
and other risk factors identified from time to time in the Company's public filings. 
 
 
-30- 
 
FOR FURTHER INFORMATION PLEASE CONTACT: 
 
Ondine Biomedical Inc. 
Carolyn Cross 
Chairman and CEO 
[e-mail] 
www.ondinebio.com 
 
OR 
 
Canaccord Genuity Limited, Nominated Adviser 
Mark Williams/Bhavesh Patel 
[phone] 
 
 
Ondine Biomedical Inc.